These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 6194679)
1. Importance of metabolites in antiarrhythmic therapy. Woosley RL; Roden DM Am J Cardiol; 1983 Sep; 52(6):3C-7C. PubMed ID: 6194679 [TBL] [Abstract][Full Text] [Related]
2. Metabolites of cardiac antiarrhythmic drugs: their clinical role. Kates RE Ann N Y Acad Sci; 1984; 432():75-89. PubMed ID: 6441496 [TBL] [Abstract][Full Text] [Related]
3. Metabolites of antiarrhythmic drugs: are they clinically important? Kates RE Ration Drug Ther; 1986 May; 20(5):1-5. PubMed ID: 3097754 [No Abstract] [Full Text] [Related]
4. Clinical pharmacokinetics of the newer antiarrhythmic agents. Gillis AM; Kates RE Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721 [TBL] [Abstract][Full Text] [Related]
5. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. Woosley RL; Echt DS; Roden DM Am J Cardiol; 1986 Jan; 57(3):25B-33B. PubMed ID: 3080860 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of antiarrhythmic drugs. Harrison DC; Meffin PJ; Winkle RA Prog Cardiovasc Dis; 1977; 20(3):217-42. PubMed ID: 335439 [No Abstract] [Full Text] [Related]
7. Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment. Nestico PF; Morganroth J Cardiol Clin; 1986 May; 4(2):285-303. PubMed ID: 3085932 [TBL] [Abstract][Full Text] [Related]
8. New drugs in the management of ventricular arrhythmias. Sanna GP G Ital Cardiol; 1984 Oct; 14(10):788-97. PubMed ID: 6083894 [TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263 [TBL] [Abstract][Full Text] [Related]
10. Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. Kim SY; Benowitz NL Drug Saf; 1990; 5(6):393-420. PubMed ID: 2285495 [TBL] [Abstract][Full Text] [Related]
11. Reliability of antiarrhythmic drug plasma concentration monitoring. Follath F; Ganzinger U; Schuetz E Clin Pharmacokinet; 1983; 8(1):63-82. PubMed ID: 6404580 [TBL] [Abstract][Full Text] [Related]
13. Pharmacologic therapy of ventricular arrhythmias. Winkle RA; Glantz SA; Harrison DC Am J Cardiol; 1975 Oct; 36(5):629-50. PubMed ID: 1103605 [TBL] [Abstract][Full Text] [Related]
14. Series on pharmacology in practice. 2. Antiarrhythmic drug therapy. Federman J; Vlietstra RE Mayo Clin Proc; 1979 Aug; 54(8):531-42. PubMed ID: 459565 [TBL] [Abstract][Full Text] [Related]
15. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias. Anderson JL Am J Cardiol; 1990 Feb; 65(8):32D-40D. PubMed ID: 2106254 [TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements. Follath F J Cardiovasc Pharmacol; 1991; 17 Suppl 6():S74-6. PubMed ID: 1723123 [TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of old and new antiarrhythmic drugs. Siddoway LA; Roden DM; Woosley RL Cardiovasc Clin; 1985; 15(3):199-248. PubMed ID: 2870805 [TBL] [Abstract][Full Text] [Related]
18. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092 [TBL] [Abstract][Full Text] [Related]